Human Genome's new lupus drug repeats success in trial, stock jumps

Back in early July, Human Genome Sciences Inc. (HGSI) shares jumped over 230 percent in one day after the pharmaceutical company said its experimental lupus drug had succeeded in a late-stage clinical trial, silencing many of its skeptics. If you decided then that a 230 percent move was all that HGSI shares had in them, you didn't anticipate today's 30-plus percent rise.

On Monday, Human Genome announced that its experimental lupus drug Benlysta was successful in a second large, late-stage clinical trial, which was needed for the company to file for FDA approval of the treatment. If approved, Benlysta would the first new treatment for the disease in 50 years.